| Literature DB >> 34034759 |
Anna Kowalczuk1, Nabila Bourebaba2,3, Katarzyna Kornicka-Garbowska2, Eliza Turlej3, Krzysztof Marycz2,4, Lynda Bourebaba5,6.
Abstract
BACKGROUND: Chronic superphysiological glucose and insulin concentrations are known to trigger several tissue and organ failures, including insulin resistance, oxidative stress and chronic low-grade inflammation. Hence, the screening for molecules that may counteract such conditions is essential in current existing therapeutic strategies, thereby the use of medicinal plant derivatives represents a promising axis in this regard.Entities:
Keywords: Calystegines; HepG2; Hyoscyamus albus; Hyperglycemia; Insulin Resistance; NF-κB; Sirt1
Mesh:
Substances:
Year: 2021 PMID: 34034759 PMCID: PMC8152357 DOI: 10.1186/s12964-021-00735-w
Source DB: PubMed Journal: Cell Commun Signal ISSN: 1478-811X Impact factor: 5.712
Sequences of primers used in qPCR
| Gene | Primer | Sequence 5'–3' | Amplicon length (bp) | Accession No |
|---|---|---|---|---|
F: R: | GTTGCCGGGTGATAGTTGGA TGCCACCTTCATGTGTCTCC | 146 | NM_033540.3 | |
F: R: | AATCTGAGGCGACTGGTGAC GGACATTGCGCTTCACCTTC | 126 | XM_024451299.1 | |
F: R: | GTGCAGAGACCGTGGAGAAA GCTGCACTGTACCCTGAGTT | 294 | NM_013987.3 | |
F: R: | CATTCCATCATTGGCCGCAC GAGCGATCCCAATCACACCA | 130 | NW_001867397.1 | |
F: R: | GGACAAACCTGAGCCCCAAT TTGGACACCAGCCGATACAG | 125 | NW_001867408.1 | |
F: R: | ACCAAGGTTTGGCCTCACAA TTGGGTCAAAGGCCAACTGT | 112 | XM_014851065.1 | |
F: R: | TCCGGGACTACACCCAGATG TCTTGGCGTTCTCCTGATGC | 108 | NM_000581.4 | |
F: R: | GACGGTGATAGCGAGCCAC TTAGGAACCACCTCCACGCAG | 173 | NM_138554.5 | |
F: R: | GCTTGGGACCTCTCTTGGAT CGAAGCCATCTTGAACACAA | 142 | NM_032409.3 | |
F: R: | CTGTTCCCCCTCATCTTCCC GTATCTGTGCTCCTCTCGCC | 113 | L19067.1 | |
F: R: | ACGGCGGTAAAGACCAGAAG CCAAGTTCAACAACCGGTGC | 89 | NM_002228.4 | |
F: R: | AAACAGATGAAGTGCTCCTTCCAG TGGAGAACACCACTTGTTGCTCCA | 391 | NM_000576.3 | |
F: R: | CTTTGCTGCCTCCAAGAACAC GCGAGTGTCCTTCTCATGGT | 97 | NM_000589.4 | |
F: R: | TCCTTCTCCACAAACATGTAACAA ATTTGTGGTTGGGTCAGGGG | 319 | NM_001318095.2 | |
F: R: | AGTGACAAGCCTGTAGCCCA GTCTGGTAGGAGACGGCGAT | 242 | NM_000594.4 | |
F: R: | AGATAGCGATGGTCTGGC TTGGGCAGTGCTCGCTTAGT | 381 | NM_001126118.1 | |
F: R: | TAGACGTCCCGTCAAATATTGC GAAGAAGCGTAAAGCGGTCC | 244 | AH002851.2 | |
F: R: | GAGCTGTGGCGTTTCACATC AGCTTCGGGCTGAAACAGT | 234 | NM_003749.3 | |
F: R: | CTGTCATCGAACGCACCT GTCTGGATGGCGGTTGTC | 178 | NM_005163.2 | |
F: R: | TCAAAGAAGGCTGGCTCCAC TGTACCCAATGAAGGAGCCG | 205 | M95936.1 | |
F: R: | TTTAATCTGCCAGGCGGAGG CCAGAATTCCATGGGGCAGT | 151 | NM_006218.4 | |
F: R: | ACCAAGAAGCTGAGCGAGTGTC ACAAAGATGGTCACGGTCTGCC | 356 | XM_011527191.1 | |
F: R: | ATCGCCCTGTGGATGACTGAG CAGCCAGGAGAAATCAAACAGAGG | 129 | NM_000633.2 | |
F: R: | AGAAGAGGCTGGTGGCTATTT CCCGCCATTAGCGCATCAC | 169 | NM_001220777.1 | |
F: R: | CTCTGGTTTTCGGTGGGTGT CTTCCATGTATGATCTTTGGTTCC | 136 | NM_004346.4 | |
F: R: | CAGGCCCCATATGATCGAGG CTGGCCTGTGTCCTCTAAGC | 142 | NM_032996.3 | |
F: R: | TCACTGCACCACTTGAGTCC ACAGGTTGCGGGAATCCAAA | 73 | NM_012238.5 | |
F: R: | CTCTGGCCCCTTTCACCATA GCTTTCTTCTTGGCAGCTCG | 229 | XM_011535010.2 | |
F: R: | CACTTCCGTGCCCCTGATAA AGTATACACCTGCTGTGCCC | 95 | NM_000151.4 | |
F: R: | GTCAGTGGTGGACCTGACCT CACCACCCTGTTGCTGTAGC | 256 | NM_001289746.1 |
Mfn1, Mitofusin 1; Mfn2, Mitofusin 2; Parkin, Parkin RBR E3 ubiquitin protein ligase (PARK2); Pink1, PTEN-induced putative kinase 1; Sod1 (Cu/Zn SOD), Copper-zinc-dependant superoxide dismutase (CuZnSOD; Sod2 (Mn SOD), Manganese-dependent superoxide dismutase (MnSOD); CAT, Catalase; GPx, Glutathione Peroxidase; TLR4, Toll like receptor 4; NF-kB-p65, Nuclear Factor-kappa-B transcription factor p65; c-Jun, Jun Proto-Oncogene, AP-1 Transcription Factor Subunit; IL-1β, Interleukin 1 beta; IL-4, Interleukin 4; IL-6, Interleukin 6; TNF-α, Tumor Necrosis Factor alpha; P53, tumor suppressor p53; Insr, Insulin Receptor; Irs2, Insulin Receptor Substrate 2; Akt1, Serine/threonine 308 Kinase 1; Akt2, serine/threonine kinase 2; Pi3k, Phosphoinositide 3-Kinase; Bcl-2, B-cell lymphoma 2; Bax, BCl-2 associated X protein; p21, Cyclin-dependent kinase inhibitor 1; Casp3, Caspase 3; Casp9, Caspase 9; Sirt1, Sirtuin 1; Foxo1, forkhead box O1; G6PC, Glucose 6 phosphate Catalytic subunit; GADPH, Glyceraldehyde-3-phosphate dehydrogenase
List of antibodies employed for proteins profiling using western blot analysis
| Antibody | Dilution | Catalog No |
|---|---|---|
| 1:1000 | Invitrogen, MA1-10865 | |
| 1:1000 | Invitrogen, 44-609G | |
| 1:1000 | Invitrogen, PA5-83748 | |
| 1:1000 | ARP32386 | |
| 1:500 | nb100-240 | |
| 1:1000 | Biorbyt, orb304547 | |
| 1:1000 | Biorbyt, orb15028 | |
| 1:2000 | Sigma Aldrich, a2066 |
Insr, Insulin Receptor; Akt, Protein Kinase B; Pi3kCD, Phosphatidylinositol 3-Kinase; SIRT1, Sirtuin 1; TOR/wTOR, Target of rapamycin/Mammalian Target of rapamycin; NF-kappaB p65(phospho-T254), Phosphorylated Nuclear Factor-kappa-B transcription factor p65; JNK1/JNK2(phospho-Thr183/Tyr185), Phosphorylated c-Jun N-terminal kinase
Fig. 1GC–MS phytochemical screening of Hyoscyamus albus calystegines isolated from seeds. Concentrations are given as μg calystegines/g DW of seeds. Identification and analysis were based on the monitoring of the following ions in a scanning mod: 217 m/z: calystegines B; 229 m/z: calystegine B2; 156 m/z: calystegines A; 390 m/z: calystegine N1; 375 m/z: calystegine C1; 189 m/z: calystegine B1; 71 m/z: octadecane; 1: calystegine A5; 2: calystégine A3; 3: calystegineA5 Gly.; 4: calystegine B4; 5: calystegine B1; 6: calystegine N1; 7: calystegine B2 [27, 29]
Fig. 2Effect on cell proliferation, viability and apoptosis of H. albus calystegines on HepG2 cells. a Histograms represent the average absorbance at 600 nm of the Alamar Blue assay. b Representative dot-plots for Annexin V & Dead Cell assay c Bar-charts depicting the quantitative analysis of live, early, and late apoptosis and cell death. d Relative gene expression of main apoptotic markers normalized to GAPDH housekeeping gene. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of treated group to untreated healthy cells. * p < 0.05, ** p < 0.01, *** p < 0.001. Control: HepG2 healthy untreated cells; H. albus_Caly: HepG2 cells treated with 250 μg/ml of the total calystegines extracted from Hyoscyamus albus seeds for 24 h
Fig. 3Influence of total calystegines pre-treatment on HepG2 cells viability and apoptosis challenged by prolonged exposure to high insulin and glucose levels. a Cell proliferation assessed by the Tox8 assay. b Representative apoptosis profile plots from flow cytometry analysis. c Quantitative estimation of Annexin V/7-AAD positive and negative cells. d Relative expression quantitation of main apoptosis-associated markers levels. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of IR group to untreated healthy cells. A hashtag (#) indicates a comparison of IR group pre-treated with calystegines to IR untreated healthy cells. */#p < 0.05, **/##p < 0.01, ***/###p < 0.001. HepG2_HE: HepG2 healthy untreated cells; HepG2_IR: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose. HepG2_IR-H. albus_Caly: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose and pre-treated with 250 μg/ml calystegines extracted from Hyoscyamus albus seeds
Fig. 4Impact of calystegines preconditioning on caspases expression and activation over HI/HG induction of HepG2 cells. a Representative plots from the Muse™ MultiCaspase Assay. b Bar charts depict the percentage of total cells with multicaspase enzyme activation. c mRNA expression of caspase‐3 and caspase-9 assayed by quantitative real‐time polymerase chain reaction (PCR). Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of IR group to untreated healthy cells. A hashtag (#) indicates a comparison of IR group pre-treated with calystegines to IR untreated healthy cells. */#p < 0.05, **/##p < 0.01, ***/###p < 0.001. HepG2_HE: HepG2 healthy untreated cells; HepG2_IR: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose. HepG2_IR-H. albus_Caly: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose and pre-treated with 250 μg/ml calystegines extracted from Hyoscyamus albus
Fig. 5Effect of calystegines on glucose uptake and gluconeogenesis regulation in IR HepG2 cells. a Representative photomicrographs of 2-NBDG uptake assay obtained by confocal epi-fluorescent microscopy; Bar size 20 μm; magnification × 60. b 2-NBDG/DAPI relative fluorescence ratio quantification. c Expression of gluconeogenic genes evaluated by qRT-PCR. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of IR group to untreated healthy cells. A hashtag (#) indicates a comparison of IR group pre-treated with calystegines to IR untreated healthy cells. */# p < 0.05, **/## p < 0.01, ***/### p < 0.001. HepG2_HE: HepG2 healthy untreated cells; HepG2_IR: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose. HepG2_IR-H. albus_Caly: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose and pre-treated with 250 μg/ml calystegines extracted from Hyoscyamus albus seeds
Fig. 6regulatory potential of calystegines on Sirt/mTOR axis in the course of IR induced in HepG2 cells. a Average relative expression of Sirt1 gene normalized to houskeeping GAPDH gene. b Relative quantitative abundance of Sirt1 and mTOR proteins obtained from western blot analysis. c Representative immunoblots for each assayed protein detected by chemiluminescence. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of IR group to untreated healthy cells. A hashtag (#) indicates a comparison of IR group pre-treated with calystegines to IR untreated healthy cells. */#p < 0.05, **/##p < 0.01, ***/###p < 0.001. HepG2_HE: HepG2 healthy untreated cells; HepG2_IR: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose. HepG2_IR-H. albus_Caly: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose and pre-treated with 250 μg/ml calystegines extracted from Hyoscyamus albus seeds
Fig. 7Effect of total calystegines on collapsed insulin signalling pathway in HI/HG HepG2 cells. a Quantitative analysis of insulin signalling-related proteins expression using western blot. b Representative blots images of insulin signalling-related proteins profiling. c Relative genes expression of key insulin signalling regulators. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of IR group to untreated healthy cells. A hashtag (#) indicates a comparison of IR group pre-treated with calystegines to IR untreated healthy cells. */#p < 0.05, **/##p < 0.01, ***/###p < 0.001. HepG2_HE: HepG2 healthy untreated cells; HepG2_IR: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose. HepG2_IR-H. albus_Caly: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose and pre-treated with 250 μg/ml calystegines extracted from Hyoscyamus albus seeds
Fig. 8Impact of calystegines treatment on oxidative stress and mitochondrial dysfunction in HI/HG challenged HepG2 cells. a1 Representative plots for events distribution from Muse Oxidative Stress Assay. a2 Representative dot plots for Muse Mitopotential Assay. b1 Level of intracellular ROS formation represented by the percentage of ROS positive cells. b2 Histograms showing the average percentages of total cells exhibiting depolarized mitochondria. c Relative gene expression of Sod1, Sod2, Cat and GPx antioxidant enzymes transcripts. d Illustration of confocal micrographs for cells labelled with MitoRed fluorescent dye; scale bar size 20 μm; magnification set at 60-folds. e Quantification of MitoRed fluorescent intensities using the pseudo ratio ΔF/F0. f Bar-charts demonstration the levels of main mitochondrial dynamics-related mRNAs. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of IR group to untreated healthy cells. A hashtag (#) indicates a comparison of IR group pre-treated with calystegines to IR untreated healthy cells. */#p < 0.05, **/##p < 0.01, ***/###p < 0.001. HepG2_HE: HepG2 healthy untreated cells; HepG2_IR: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose. HepG2_IR-H. albus_Caly: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose and pre-treated with 250 μg/ml calystegines extracted from Hyoscyamus albus seeds
Fig. 9Effect of total calystegines on the NF-κB/JNK/TLR4 inflammatory pathway triggered by insulin resistance condition in HepG2 cells. a Relative gene expression of c-Jun, NF-κB and Tlr4 factors. b Quantitative representation of total NF- κB p65 and JNK1/2 proteins. c Quantitative representation of phosphorylated NF- κB p65(T254) and JNK(Thr183/Tyr185) proteins. d Representative chemiluminescent blots for analysed proteins. e Relative levels of main pro-inflammatory cytokines transcripts. Representative data from three independent experiments are shown ± SD (n = 3). An asterisk (*) indicates a comparison of IR group to untreated healthy cells. A hashtag (#) indicates a comparison of IR group pre-treated with calystegines to IR untreated healthy cells. */#p < 0.05, **/##p < 0.01, ***/###p < 0.001. HepG2_HE: HepG2 healthy untreated cells; HepG2_IR: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose. HepG2_IR-H. albus_Caly: Insulin resistant HepG2 cells exposed to high concentrations of insulin and glucose and pre-treated with 250 μg/ml calystegines extracted from Hyoscyamus albus seeds